Prescript: It’s been a while since I’ve written, I know. I had a beautiful baby boy who is now nearly six months old. Perfect and perfectly healthy, so take that, diabetes! This post is about other things, though. Four years … Read more
JDRF has announced a two partnerships to support the development soluble glucagon formulations—an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).
Five adults in the UK with type 1 diabetes have used an artificial pancreas in their homes without medical supervision. This step offers real hope for a future where people with type 1 diabetes no longer have to monitor blood glucose levels, and where they have a better chance of living a long and healthy life. Read more
JDRF and Tandem Diabetes Care, the company behind the t:slim insulin pump, have teamed up to develop a dual-chamber infusion pump for the management of diabetes. The partnership agreement is designed to accelerate the development of a next-generation, fully automated artificial pancreas system. Read more
The Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH) has awarded Biodel Inc. a grant for the development of novel and stable glucagon formulations for use in an artificial pancreas, also known as a closed loop pump system.
The SBIR program is a highly competitive program that encourages domestic small businesses to engage in Federal Research/Research and Development that has the potential for commercialization. Read more
Positive results from the first feasibility study of an advanced first-generation artificial pancreas system were presented at the 72nd Annual American Diabetes Association Meeting in Philadelphia. Findings from the study indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System… Read more
JDRF and Dexcom announced that they have formed a partnership whose goal is to accelerate the development of a novel wireless “smart transmitter” that would allow a continuous glucose monitor (CGM) system to communicate directly with an artificial pancreas… Read more
The U.S. Food and Drug Administration (FDA) has approved the first outpatient artificial pancreas trial in the United States, marking a critical development in the effort by JDRF and its allies to bring this innovative and lifesaving diabetes technology to people with type 1 diabetes… Read more
The U.S. Food and Drug Administration (FDA) issued draft guidance designed to help investigators and manufacturers as they develop and seek approval for artificial pancreas device systems to treat type 1 diabetes. This step comes after a large campaign led by the Juvenile Diabetes research Foundation … Read more
Diabetes technology has vastly improved in the last decade, and most people with diabetes who have the opportunity to wear an insulin pump or a continuous glucose monitor are grateful for the assistance they provide. But even with these advanced tools, the biggest burdens of diabetes – the insulin dosing and blood sugar testing – still lie on the person with diabetes or a caregiver. Read more